TBWA
CRVS icon

Three Bridge Wealth Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Three Bridge Wealth Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$327K Hold
22,371
– – 0.09% 70
2025
Q4 		$172K Hold
22,371
– – 0.05% 90
2025
Q3 		$165K Hold
22,371
– – 0.04% 87
2025
Q2 		$89.5K Hold
22,371
– – 0.02% 123
2025
Q1 		$71.1K Hold
22,371
– – 0.02% 84
2024
Q4 		$120K Buy
+22,371
New +$167K 0.04% 93

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Three Bridge Wealth Advisors's CRVS Position: Q1 2026 in Review

Three Bridge Wealth Advisors held its Corvus Pharmaceuticals (CRVS) position steady in Q1 2026 at 22,371 shares worth $327K. The position accounts for 0.09% of the portfolio, ranked #70.

Three Bridge Wealth Advisors first reported a position in CRVS in Q4 2024 and has held it in 6 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Three Bridge Wealth Advisors held 22,371 shares of Corvus Pharmaceuticals worth $327K as of Q1 2026.
  • Three Bridge Wealth Advisors left its Corvus Pharmaceuticals share count unchanged in Q1 2026.
  • Corvus Pharmaceuticals made up 0.09% of Three Bridge Wealth Advisors's portfolio in Q1 2026, its #70 holding.
  • Three Bridge Wealth Advisors first reported a position in Corvus Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Three Bridge Wealth Advisors's 13F filing for Q1 2026, filed 12 May 2026.